As WPP faces break-up calls in the wake of Sir Martin Sorrell's exit, the agency holding company model is under greater scrutiny than at any time since the 1980s.
Novartis' top lawyer exits after Cohen payments; More states file suit against Purdue Pharma; J&J to relaunch baby line.
Whether jurors will award a pharma Grand Prix, and whether US pharma will show up, are two open questions in the run-up to Lions Health.
Shields will serve as president of the Think Patients subsidiary firm.
Feds join whistleblower case against Insys; Kleiner Perkins Caufield partner Seidenberg departs; Lilly strikes second acquisition deal in a week.
To say that Sir Martin Sorrell's rapid departure from WPP was a seismic event is an understatement. So just what happened in the days leading up to the fall of its CEO?
Pharma stocks were up after the President went easy on drugmakers.
Beam Therapeutics raises $87 million in Series A funding; Trump drug-pricing plan largely spares big pharma; Novartis regrets Cohen consulting pact.
WPP's interim leadership team insists there will be no wholesale break-up of the group.
Roberto Quarta faces a potential shareholder revolt at next month's AGM after advisory group Glass Lewis recommended that shareholders vote against his re-election.
Here's a recap of the Novartis-Michael Cohen crisis, which unfolded this week, including how the drugmaker has responded to scrutiny over its $1.2 million contract with Cohen's firm.
Trump on drug pricing; Alexa breaks into healthcare; Merck's experimental Ebola vaccine headed to Congo outbreak.
Botox Cosmetic has rolled out its first ad campaign focused on reaching male customers.
At the Asembia Specialty Pharma summit, speakers described a healthcare ecosystem in which specialty products will represent nearly half of all drug spending.
Novartis discloses $1.2 million Cohen payment; FDA calls for two stem cell companies to halt operations; Eli Lilly to buy Armo Biosciences for $1.6 billion
Isenberg replaces Kym White, who left the PR agency in March to join Vertex Pharmaceuticals.
Novartis payments to Trump lawyer made public; Cardinal Health apologizes for mass painkiller shipments; Valeant plans rebranding.
Thanks to legalization, a new breed of startups are changing the nature of cannabis advertising.
The former WPP CEO said on Tuesday at Techonomy NYC 18 that he's not planning to retire.
Takeda, Shire reach a deal; Walmart to restrict opioid prescriptions; Glaxo launches global media review.
Pharma giant GlaxoSmithKline has reportedly launched a review of its $1.76 billion global media agency arrangements, putting MediaCom and PHD on alert.
The healthcare sector has suffered a dip in public trust in major markets including France, India and the US, but Britons remain among the more trusting globally, according to the Edelman Health Trust Barometer.
Elliott makes offer for AthenaHealth; J&J releases data from esketamine late-stage trial; Roche wins fast Tecentriq review from FDA.
For all the talk about "legacy," industry experts are struggling to agree on how Martin Sorrell will be remembered in years to come.
Both leaders were honored at Healthcare Businesswomen's Association 2018 Woman of the Year event in New York.
Record year for brands, fewer celebrities, lower volume of entries expected and much more.
Daraprim retains high price tag despite Shkreli sentencing; Merck invests $125 million in Moderna; Cigna posts better-than-expected Q1 earnings.
Four agencies are making a difference by supporting nonprofits, educating and empowering youth, and promoting wellness and sustainability in communities around the world
FDA and HHS officials talk drug pricing fixes; Merck pushes for another Keytruda approval; CVS reports better-than-expected Q1 earnings.
Intriguing data on the economics and impact of co-pay coupons and programs
Rbb Communications' EVP of global and emerging markets, healthcare Srikant Ramaswami discusses how he keeps sane with his busy schedule and what inspires him.
J&J's Janssen to buy BeneVir; Regulators approve new use of Kymriah; Deaths from synthetic opioids surpass prescription opioids.
Opdivo's commercial potential will likely take a hit in the wake of new Keytruda data, but the impact may depend on the ability of BMS to market the message that its I-O/I-O combo allows patients to delay chemo.
The unit was up 6% in the first quarter.
Fitbit partners with Google Cloud to make health data more shearable; Regeneron, Sanofi to slash price of Praluent for Express Scripts customers; Novo Nordisk teams up with startup to help diabetes patients.
Here are the 40 upstarts and veterans who are transforming the healthcare industry.
The National Association of Cannabis Businesses has released the first national advertising rules for the cannabis industry.
Mark Read has said WPP needs to focus more on clients and less on how it organizes itself.
Allergan migraine drug meets Phase III endpoints; WPP unit with health and wellness shops up 2% in Q1; Watchdog groups question CDC director's salary.
Revenue for WPP's health and wellness, brand consulting, and specialist communications unit grew 2% in first quarter of 2018 to $1.47 billion.
WPP's former chief executive Sir Martin Sorrell was paid a (relatively) measly £13.9m by the company in 2017, its annual report shows.
Trump looks for another VA nominee; CRISPR company Mammoth launches; Why autism cases are increasing.
The Lions Health part of the festival will take place on June 18 and 19
Havas has announced it is co-operating with authorities following the shock arrest of Vincent Bolloré.
FDA gives Acadia's Nuplazid another look; Americans for Prosperity launches campaign for "right to try"; Juno cofounder exits.
He is joining the pharma company from Archer Daniels Midland.
His wife, Jill Connick, also played a role in The New 50 campaign.
Takeda investors unhappy with preliminary Shire deal; New drug sales drive Amgen earnings; Novartis debuts mobile app for eye disease study.
The billionaire recently stepped down as chairman of Vivendi.
But threats to the industry loom as brands take work in-house.
The firm's Narcan product is more than just a lifesaving treatment for opioid overdose. It's a brilliant, salient campaign, as well.
Amgen and Novartis enlisted Arnold Worldwide, Wavemaker, and Starcom Media Group for its Speak Your Migraine campaign.
Express Scripts pressures Amgen on migraine medicine list price; Takeda, Shire get closer to deal; Sanofi R&D chief steps down.
Takeda makes higher offer for Shire; Prothena pulls plug on AL amyloidosis drug; Henry Schein to spin off animal health unit.
A deal with Sandoz to lead the global launch of Pear's two lead products puts marketing muscle behind the nascent class of 'prescription digital therapeutics.'
Novocure and Glue Advertising put on a Facebook Live event promoting the cancer treatment Optune in March.
Allergan reverses course on Shire deal; Merck seeks partners for cancer, immune system drugs; J&J diversified vision portfolio and it's paying off.
Procter & Gamble said its $4.2 billion acquisition of German firm Merck's consumer health division was about allowing it to respond to the changing demands of an aging world.
Nearly a quarter (22%) of all marcomms M&A deals involved private-equity funds — double the 11% seen in the last two quarters of 2017.
Allergan enters bidding war for Shire; Opioid prescriptions drop in 2017; Novartis Q1 numbers disappoint.
WPP's joint chief operating officers Mark Read and Andrew Scott have said they do not believe a break-up of the ad group makes sense.
Seifert said feedback from clients has been positive.
As with most drug pricing battles, patients yet again are caught in the crossfire.
Sanders introduces opioid bill; GW gets nod from FDA for Epidiolex; Sanofi sells generic unit to Advent for $2.4 billion.
You've seen what the biggies can do. What about the smaller end of the spectrum? MM&M's second buyer's guide to pharma, healthcare, and life sciences consulting services focuses on the dos and don'ts of hiring boutique firms.
The healthcare marketing group made another major acquisition in the country last month.
Omnicom's healthcare revenue was up 2.7% in Q1
J&J Q1 numbers beat expectations; Amazon scraps pharma product distribution plan; FDA works to develop regulatory processes for AI.
Campaign looks back at some of Sir Martin Sorrell's musings, barbs and pearls of wisdom in recent times.
The firm hired five senior staff in the past month.
Shire sale of oncology business makes it more affordable for Takeda; FDA reverses course on Alkermes depression drug; Sorrell out as WPP CEO.
As Sir Martin clears his desk, PRWeek has collected nine thoughts from the worlds of PR, journalism and agency life on the man, his skills, his temperament, and his future.
Martin Sorrell's resignation as chief executive of WPP could lead to a breakup of the company and spark other major changes.
John Tylee examines how a man who never ran an agency rose to become such a dominant force.
Martin Sorrell has stood down as chief executive of WPP, the company has announced.
WPP's board of directors is set to meet as it awaits the outcome of an investigation into the personal conduct of CEO Martin Sorrell.
FDA investigates unapproved herpes vaccine; DC launches PReP campaign; J&J ordered to pay $80 million in damages in asbestos suit.
She is relocating to Switzerland for the role.
The Facebook CEO did not wilt during this week's marathon Senate session.
U.S. deals through the end of March increased 366% compared with last year.
The pharma giant will take up 15 floors of a new Manhattan skyscraper.
Sonderman had worked at GSW since 2001.
GCI Health, HealthyWomen, and Redbook magazine are using survey insights to inform the HealthiHer movement.
Alexion buys Wilson in latest pharma deal; Drug performance software company Aetion gets financial backing; Roche stops enrollment in combo study after patient deaths.
Despite the US Congress's lack of insight into Facebook's operations, Mark Zuckerberg's handling of the situation seems to have restored investor confidence in the company.
Read the April 2018 issue in its entirety.
The 2018 MM&M/Publicis Health Diversity Survey is open.
White House to allow states to determine health benefits required by Obamacare; FDA orders Essure sales restrictions; Researchers recommend redefining Alzheimer's.
Turett spent 25 years at Edelman before launching her own firm in 2013.
Gillespie will report to W2O president Jennifer Gottlieb.
The industry is being disrupted and marketers are part of the equation.
WPP's investigation into alleged misconduct by founder and chief executive Sir Martin Sorrell could be concluded by next week, according to reports.
Novartis to buy AveXis; Merck lung cancer drug meets primary goal in trial; "Pharma bro" duo expose more drug pricing flaws.
Actor Patrick Dempsey is helping patients get over the pressure of scheduling an appointment
Facebook puts hospital patient data project on hold; Pharma companies' spending on advocacy under the microscope; Naloxone made more widely available.
She will lead Nuvo Group's U.S. operations and head marketing globally.
Gottlieb asks for internet providers' help fighting opioid crisis; Ferring acquires Rebiotix; AbbVie reaches deal with Biogen to delay Humira rival.
With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.
Obamacare signup total misses 2017 numbers; Feds warn of "nightmare bacteria"; Lilly, startup reach $473 million deal on diabetes work.
The 2017 numbers aren't kind to print-first publishers. Is this a blip in print's fortunes or the start of a long-predicted decline?